Guolan Lu

Assistant Professor @Stanford, NIH K99/R00 Fellow @NIH #NCI

[Guolan Lu @GuolanLu]

1/8 ✨Thrilled to share that our paper is now online
@NatureBiotech
“Single-cell spatial pharmacobiology identifies conserved stromal barriers to therapeutic antibody delivery in human solid tumors”
https://t.co/Gm5vVtduHT
(open access): https://t.co/UuxG8JJC2M

[Guolan Lu @GuolanLu]

8/8 💜 We especially thank the patients and their families for participating in the clinical trials and contributing tissue samples that made this research possible.

🏛️ We also thank our funding sources, including @theNCI, @AmericanCancer, @StanfordCancer, and @StanfordMIPS.

[Guolan Lu @GuolanLu]

1/8 ✨Thrilled to share that our paper is now online
@NatureBiotech
“Single-cell spatial pharmacobiology identifies conserved stromal barriers to therapeutic antibody delivery in human solid tumors”
https://t.co/Gm5vVtduHT
(open access): https://t.co/UuxG8JJC2M

[Guolan Lu @GuolanLu]

7/8 🙏 This project has been a long journey, and I am deeply grateful to my extraordinary postdoctoral mentors @EbenRosenthal and @GarryPNolan for their guidance and support throughout this work.

🤝 And to our wonderful collaborators @johnhickey22 @Max_Haist @Loloabn @ErnaForgoMD @marc_a_baertsch @xavi_r_c @nsvdb @poultsides and many others not on Twitter/X.

[Guolan Lu @GuolanLu]

6/8 💡The SSP platform is broadly applicable to antibody-based therapeutics, including immune checkpoint inhibitors, antibody-drug conjugates, and multi-specific antibodies. 
Incorporating SSP into early-phase clinical trials could advance the development of next-generation cancer therapeutics by uncovering mechanisms of response and resistance, guiding individualized dosing and identifying spatial biomarkers for participant stratification.

[Guolan Lu @GuolanLu]

5/8 💡 These results suggest that improving antibody therapy may require not only better targets, but also strategies to overcome spatial barriers within the tumor microenvironment.

[Guolan Lu @GuolanLu]

6/8 💡The SSP platform is broadly applicable to antibody-based therapeutics, including immune checkpoint inhibitors, antibody-drug conjugates, and multi-specific antibodies. 
Incorporating SSP into early-phase clinical trials could advance the development of next-generation cancer therapeutics by uncovering mechanisms of response and resistance, guiding individualized dosing and identifying spatial biomarkers for participant stratification.

[Guolan Lu @GuolanLu]

5/8 💡 These results suggest that improving antibody therapy may require not only better targets, but also strategies to overcome spatial barriers within the tumor microenvironment.

[Guolan Lu @GuolanLu]

@StanfordUrology @StanfordCancer @StanfordMIPS @stanfordimmuno @stanfordcbio @bioe_stanford @StanfordBioX

[Guolan Lu @GuolanLu]

Please RT: The Lu Lab at Stanford is hiring a postdoc in Spatial Biology & Therapeutics. Comp bio, cancer bio, and cancer therapeutics backgrounds welcome. Available immediately; start date flexible. Details in attached ad. Apply: [email protected].
Lab website:https://t.co/8Eh0k4gv7u

[Guolan Lu @GuolanLu]

@AaronNewmanLab @Nature Congratulations, Aaron!

[Guolan Lu @GuolanLu]

@AttardiLaura @theNASciences Congratulations, Laura! So well-deserved!

[Guolan Lu @GuolanLu]

Congratulations Joe! Wonderful news for the department, and I’m excited to see your leadership, vision, and dedication guide us into the next chapter. 🎉

[Stanford Urology @StanfordUrology]

We are pleased to announce the appointment of Joseph Liao, MD, as the next Chair of the Department of Urology, effective August 1.

Read the full announcement from Dean Lloyd Minor: https://t.co/jfom0VEeff

@liaojoe1 @StanfordMed @AmerUrological